NCT03855358: An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

NCT03855358
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrollable symptoms of brain metastasis
https://ClinicalTrials.gov/show/NCT03855358

Comments are closed.

Up ↑